New hope for advanced cervical cancer: major trial tests promising drug combo
NCT ID NCT04982237
Summary
This large, late-stage study is testing whether adding a new immunotherapy drug called AK104 to standard chemotherapy helps women with advanced cervical cancer that has returned or spread. The goal is to see if this combination can better control the cancer, helping patients live longer without their disease getting worse. The study is comparing the new combination against standard treatment alone in about 445 women.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, China
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
-
The Second Affiliated Hospital,Anhui Medical University
Hefei, China
-
Women's Hospital School Of Medicine Zhejiang University
Hangzhou, China
-
Zhejiang Cancer Hospital
Hangzhou, China
Conditions
Explore the condition pages connected to this study.